Олокизумаба (ингибитора интерлейкина-6) и RPH-104 (ингибитора интерлейкина-1)
Evgeniy Nasonov 1, Saeed Fatenejad 2, Elena Korneva 3 et al. Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study. Meeting: 2019 ACR/ARP Annual Meeting. Date of first publication: October 23, 2019.
Takeuchi T, Tanaka Y, Yamanaka H et al. Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. Mod Rheumatol. 2016;26(1):15-23. doi: 10.3109/14397595.2015.1074648. Epub 2015 Sep 10.
Genovese MC, Fleischmann R, Furst et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014 Sep;73(9):1607-15. doi: 10.1136/annrheumdis-2013-204760. Epub 2014 Mar 18.